Krista Honkonen

TL;DR: Results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema.

TL;DR: Lymphangiogenic growth factors improve lymphatic vessel regeneration and lymph node function after lymph node transfer and provide a basis for future clinical trials in lymphedema patients.

TL;DR: The results show that VEGF-C provides the preferred alternative for growth factor therapy of lymphedema when compared to VEGf-C156S, due to the superior lymphangiogenic response and minor blood vessel effects, and suggest that activation of both VEGFR-2 and V EGFR-3 might be needed for efficient lymphANGiogenesis.

TL;DR: Hypoxia‐inducible factors (HIFs) upregulate the expression of angiogenic mediators together with genes involved in energy metabolism and recovery of ischaemic tissues and HIF‐2α is a novel factor.

TL;DR: The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia and ischemic heart failure and is feasible for the development of new therapeutic approaches.